Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP3 | P05413 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | NR5A2 | O00482 | 1/20 | 0.52 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | ESR1 | P03372 | 1/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.51 |
| ▸ | CDC25A | P30304 | 1/20 | 0.51 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.51 |
| ▸ | AKT1 | P31749 | 1/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | DGKA | P23743 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | P2RY10 | O00398 | 4/20 | 0.47 |
| ▸ | GPR34 | Q9UPC5 | 2/20 | 0.47 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.46 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1643923 | 1.00 | FABP3 (0.62) | FABP3SMN1; SMN2NR5A2NR5A1LMNA | |
| SCHEMBL5190825 | 1.00 | FABP3 (0.62) | FABP3SMN1; SMN2NR5A2NR5A1LMNA | |
| SCHEMBL515226 | 0.92 | FABP3 (0.56) | FABP3P2RY10GPR34 | |
| SCHEMBL9027639 | 0.92 | FABP3 (0.56) | FABP3P2RY10GPR34 | |
| SCHEMBL20472539 | 0.92 | FABP3 (0.56) | FABP3P2RY10GPR34 | |
| SCHEMBL52780 | 0.92 | FABP3 (0.56) | FABP3P2RY10GPR34 | |
| SCHEMBL16180754 | 0.89 | FABP3 (0.53) | FABP3P2RY10GPR34 | |
| SCHEMBL3630629 | 0.87 | FABP3 (0.72) | FABP3SMN1; SMN2NR5A2NR5A1LMNA | |
| SCHEMBL3631867 | 0.87 | FABP3 (0.72) | FABP3SMN1; SMN2NR5A2NR5A1LMNA | |
| SCHEMBL3629744 | 0.87 | FABP3 (0.72) | FABP3SMN1; SMN2NR5A2NR5A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8703179-B2 | Mucosal formulation | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2014-04-22 | — | — | US | claimed |
| WO-2007133261-A1 | MUCOSAL FORMULATION | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2007-11-22 | — | — | WO | claimed |
| US-20070264206-A1 | Mucosal formulation | KIMBERLY-CLARK WORLDWIDE, INC. | 2007-11-15 | — | — | US | claimed |
| US-20260097150-A1 | Implantable Device for Treating an Ocular Condition | CELANESE EVA PERFORMANCE POLYMERS LLC (US) | 2026-04-09 | — | — | US | disclosed |
| US-20260096984-A1 | Implantable Device for Administering a Therapeutic Agent | CELANESE EVA PERFORMANCE POLYMERS LLC (US) | 2026-04-09 | — | — | US | disclosed |
| US-20260096985-A1 | Injectable Composition For Drug Delivery | CELANESE EVA PERFORMANCE POLYMERS LLC | 2026-04-09 | — | — | US | disclosed |
| EP-4312951-A1 | IMPLANTABLE MEDICAL DEVICE FOR THE DELIVERY OF NUCLEIC ACID-ENCAPSULATED PARTICLES | Celanese EVA Performance Polymers LLC (US) | 2024-02-07 | — | — | EP | disclosed |
| US-20220313616-A1 | Implantable Medical Device for the Delivery of Nucleic Acid-Encapsulated Particles | CELANESE EVA PERFORMANCE POLYMERS LLC | 2022-10-06 | — | — | US | disclosed |
| WO-2022212300-A1 | IMPLANTABLE MEDICAL DEVICE FOR THE DELIVERY OF NUCLEIC ACID-ENCAPSULATED PARTICLES | CELANESE EVA PERFORMANCE POLYMERS LLC (US) | 2022-10-06 | — | — | WO | disclosed |
| US-8703179-B2 | Mucosal formulation | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| WO-2007133261-A1 | MUCOSAL FORMULATION | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2007-11-22 | — | — | WO | disclosed |
| US-20070264206-A1 | Mucosal formulation | KIMBERLY-CLARK WORLDWIDE, INC. | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260097150-A1 | Implantable Device for Treating an Ocular Condition | P4HTM, ITGAM, TIMM44 | FABP3 2950/4885SMN1; SMN2 2789/4885NR5A2 3250/4885 |
| US-20260096984-A1 | Implantable Device for Administering a Therapeutic Agent | GHITM, O60361, P4HTM | FABP3 3213/4885SMN1; SMN2 1272/4885NR5A2 3041/4885 |
| US-20070264206-A1 | Mucosal formulation | MUC1, CHMP4B, VMA21 | FABP3 609/4885SMN1; SMN2 3089/4885NR5A2 2597/4885 |
| US-20260096985-A1 | Injectable Composition For Drug Delivery | SAMM50, OPRM1, IRAK4 | FABP3 3623/4885SMN1; SMN2 724/4885NR5A2 1837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.